Hydrogen sulfide and the metabolic syndrome.
Hydrogen sulfide and the metabolic syndrome.
复制标题
DOI：
10.1586/ecp.10.133
复制
发表时间：
2011-01-01
影响因子：
4.4
通讯作者：
Wu, Lingyun
中科院分区：
文献类型：
--
作者：
Desai, Kaushik M;Chang, Tuanjie;Wu, Lingyun
代谢综合征是一组异常，包括肥胖、高血压、高胰岛素血症、高血糖水平和高脂血症，这些异常共同极大地增加了患心血管疾病和2型糖尿病的风险。硫化氢(H(2)S)是心血管系统中的一种血管舒张性气体递质介质，被认为是一种内皮衍生的松弛因子。血管中缺乏H(2)S及其合成酶-胱硫醚-伽马裂解酶会导致高血压，而胰腺中增加则会减少胰岛素的分泌。因此，研究正在取得进展，以确定H(2)S是否参与了代谢综合征的发病机制。几个实验室正在合成和测试临床使用的释放H(2)S的药物，其中一些化合物正在测试对代谢综合征的有效性。
The metabolic syndrome is a group of abnormalities including obesity, high blood pressure, hyperinsulinemia, high blood glucose levels and hyperlipidemia that together greatly increase the risk of developing cardiovascular disease and Type 2 diabetes. Hydrogen sulfide (H(2)S) is a vasodilatory gasotransmitter mediator in the cardiovascular system, proposed as an endothelium-derived relaxing factor. A lack of H(2)S and its synthesizing enzyme, cystathionine gamma-lyase, in the vasculature causes hypertension, whereas an increase in the pancreas reduces insulin secretion. Thus, research is making inroads to determine whether H(2)S is involved in the pathogenesis of the metabolic syndrome. Several laboratories are synthesizing and testing clinically used drugs that release H(2)S. Some of these compounds are being tested for effectiveness in the metabolic syndrome.